药石科技：公司自去年起推动大客户战略

Core Viewpoint - The company is enhancing its strategic focus on major clients by establishing a dedicated service team to improve customer response efficiency and satisfaction, while expanding its collaboration with multinational corporations (MNCs) across the entire drug development cycle [1] Group 1: Strategic Initiatives - The company has initiated a major client strategy since last year, forming a "triangular" business team consisting of client managers, solution managers, and delivery managers to provide in-depth services to strategic clients [1] - A specialized major client service team has been established this year to coordinate business development resources across regions including China, the US, and Europe, significantly improving customer response efficiency and satisfaction [1] Group 2: Collaboration with MNCs - The collaboration with MNCs has evolved from supplying molecular building blocks to a comprehensive CMC (Chemistry, Manufacturing, and Controls) service, with increasing depth and project scale [1] - The company now covers the entire R&D cycle for MNCs, including drug discovery, clinical development, and CMC services from clinical phases I-III to commercialization [1] Group 3: Innovation and Project Development - The company is leveraging its solid foundation of cooperation and client trust to enter the new molecular pipeline development field for MNCs, with ongoing projects in cutting-edge areas such as peptides (non-natural amino acid building blocks) and ADC (antibody-drug conjugates) design [1] - The company is continuously deepening its collaborative efforts in innovative therapies [1]